Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 共同教育中心
  3. 智慧醫療與健康資訊碩士學位學程
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/101743
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor黃韻如zh_TW
dc.contributor.advisorRUBY YUN-JU HUANGen
dc.contributor.author康瑪麗zh_TW
dc.contributor.authorMaria José Carbajal Hernándezen
dc.date.accessioned2026-03-04T16:13:04Z-
dc.date.available2026-03-05-
dc.date.copyright2026-03-04-
dc.date.issued2026-
dc.date.submitted2026-02-23-
dc.identifier.citation1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
2. Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747.
3. Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD. Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021;162(3):741–750.
4. Iida Y, Okamoto A, Hollis RL, Gourley C, Herrington CS. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2021;31(4):605–616.
5. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–1543.
6. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597–1601.
7. Mandai M, Yamaguchi K, Matsumura N, et al. Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment. Cancer Lett. 2011;310(1):129–133.
8. Ioannidou A, Pados G, Mastorakos G, Gkrozou F. Malignant transformation of endometriosis: molecular and clinical aspects. Best Pract Res Clin Obstet Gynaecol. 2025;93:102–115.
9. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244–1256.
10. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol. 2012;13(4):385–394.
11. Yang YM, Yang WX. Epithelial-to-mesenchymal transition in endometriosis: an updated review. Oncotarget. 2017;8(25):41679–41689.
12. Vissers G, Giacomozzi M, Verdurmen W, Peek R, Nap A. The role of fibrosis in endometriosis: a systematic review. Hum Reprod Update. 2024;30(6):706–750.
13. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98:511–519.
14. Capozzi VA, Scarpelli E, dell’Omo S, et al. Atypical endometriosis: a comprehensive systematic review of pathological patterns and diagnostic challenges. Biomedicines. 2024;12(6):1209.
15. Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376:1835–1848.
16. Suda K, Nakaoka H, Yoshihara K, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 2018;24:1777–1789.
17. Tong A, et al. Review: the progression of ovarian clear cell carcinoma – molecular, epigenetic, and microenvironmental perspectives. Gynecol Oncol Rep. 2023;48:101–111. Europe PMC
18. Howitt BE, Strickland KC, Sholl LM, et al. Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017;6(2):e1277308.
19. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. (same)
20. Laganà AS, Vitale SG, Salmeri FM, et al. Immune system and endometriosis: pathophysiology and therapeutic perspectives. J Reprod Immunol. 2017;123:87–94.
21. Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity by immune checkpoint blockade. Nat Med. 2018;24(5):556–562. doi:10.1038/s41591-018-0012-z. PubMed+1
22. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598.
23. Kinnear HM, et al. The ovarian stroma as a new frontier in tumor microenvironment research. Reproduction. 2020;160(2):R253–R266.
24. Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474(7350):179–183.
25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
26. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.
27. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98:511–519.
28. Psilopatis I, Burghaus S, Au K, Hofbeck L, Lotz L, et al. The Hallmarks of Endometriosis. Geburtshilfe Frauenheilkd. 2024;84(6):555–563.
29. Chui MH. Endometriosis: benign, malignant, or something in between? Pathology. 2014;46(5):420–429.
30. NanoString/Bruker Spatial Biology. GeoMx IO Proteome Atlas Product Bulletin. 2023–2025.
31. Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma (CCC) of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol. 2016;27(3):e31. doi: 10.3802/jgo.2016.27.e31. Semantic Scholar
32. Li M, et al. Characterization of ovarian clear cell carcinoma: molecular features, chemoresistance, and therapeutic challenges. Ovarian Res. 2017;10:6. doi:10.1186/s13048-017-0304-9. SpringerLink
33. Wong OGW, Li J, Cheung ANY. Targeting DNA damage response pathway in ovarian clear cell carcinoma. Front Oncol. 2021;11:666815. doi:10.3389/fonc.2021.666815. Frontiers
34. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
35. Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016;165(3):535–550.
36. Merritt CR, Ong GT, Church SE, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38(5):586–599.
37. Omilian AR, Sheng H, Hong CC, Bandera EV, Khoury T, Ambrosone CB, Yao S. Multiplexed digital spatial profiling of invasive breast tumors from Black and White women. Mol Oncol. 2022;16(1):54–68.
38. Aung TN, Warrell J, Martinez-Morilla S, et al. Spatially informed gene signatures for response to immunotherapy in melanoma. Clin Cancer Res. 2024;30(16):3520–3532.
39. Naei VY, Monkman J, Sadeghirad H, Mehdi A, Blick T, Mullally W, et al. Spatial proteomic profiling of tumor and stromal compartments in non-small-cell lung cancer identifies signatures associated with overall survival. Clin Transl Immunol. 2024;13(7):e1522.
40. Mateiou C, Lokhande L, Diep LH, Knulst M, Carlsson E, Ek S, et al. Spatial tumor immune microenvironment phenotypes in ovarian cancer. NPJ Precis Oncol. 2024;8(1):148.
41. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer. 2000;88:2584–2589.
42. NanoString Technologies. GeoMx® DSP Protein User Manual. Seattle (WA): NanoString Technologies; 2023.
43. NanoString Technologies. GeoMx® NGS Pipeline and Data Analysis Suite User Guide. Seattle (WA): NanoString Technologies; 2023.
44. Noel T, Wang QS, Greka A, Marshall JL. Principles of spatial transcriptomics analysis: a practical walk-through in kidney tissue. Front Physiol. 2022;12:809346.
45. Danaher P, Warren S, Dennis L, et al. Gene expression analysis of tumor microenvironments with digital spatial profiling. Nat Biotechnol. 2020;38(5):610–622.
46. Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol. 2014;32(9):896–902.
47. Worley MJ Jr, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14(3):5367–5379.
48. Rai P, Kota V, Deendayal M, Shivaji S. Differential proteome profiling of eutopic endometrium from women with endometriosis to understand etiology of endometriosis. J Proteome Res. 2010;9(9):4407–4419.
49. Tai YT, Lin WC, Ye J, et al. Spatial profiling of ovarian clear cell carcinoma reveals immune-hot features. Mod Pathol. 2025;38(1):100630.
50. Oh JH, Kim DH, Ryu SY, et al. Syndecan-1 overexpression promotes tumor growth and angiogenesis in an endometrial cancer xenograft model. Int J Gynecol Cancer. 2010;20(5):751-756. doi:10.1111/IGC.0b013e3181e02faa.
51. Guo S, Wu X, Lei T, Zhong R, Wang Y, Zhang L, et al. The role and therapeutic value of syndecan-1 in cancer metastasis and drug resistance. Front Cell Dev Biol. 2022;9:784983. doi:10.3389/fcell.2021.784983.
52. Chen W, Zhang Z, Zhang S, et al. MUC1: structure, function, and clinical application in epithelial cancers. Int J Mol Sci. 2021;22(12):6567. doi:10.3390/ijms22126567.
53. Kumari P, Dash S, Samanta D. E-cadherin: a potential biomarker in cancer and a therapeutic target. Biochim Biophys Acta Rev Cancer. 2025;1880(6):189466. doi:10.1016/j.bbcan.2025.189466.
54. Zhang Y, Chen S, Tang X, Peng Y, Jiang T, Zhang X, Li J, Liu Y, Yang Z. The role of KLRG1: a novel biomarker and new therapeutic target. Cell Commun Signal. 2024;22(1):337. doi:10.1186/s12964-024-01714-7.
55. Kumar S, Park SH, Cieply B, Schupp J, Killiam E, Zhang F, Rimm DL, Frisch SM. A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol. 2011;31(19):4036–4051. doi:10.1128/MCB.01342-10.
56. Chung KP, Huang YL, Chen YJ, Juan YH, Hsu CL, Nakahira K, et al. Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1. Mol Oncol. 2021;15(2):560–578. doi:10.1002/1878-0261.12843.
57. Tang Z, Li L, Tang Y, Xie D, Wu K, Wei W, et al. CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer. Cancer Sci. 2018;109(8):2590–2598. doi:10.1111/cas.13691.
58. Trachsel B, Imobersteg S, Valpreda G, Singer G, Grabherr R, Ormos M, et al. Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI Res. 2024;14(1):17. doi:10.1186/s13550-024-01070-0.
59. Lis-Kuberka J, Kubik P, Chrobak A, Pająk J, Chełmońska-Soyta A, Orczyk-Pawiłowicz M. Fibronectin molecular status in plasma of women with endometriosis and fertility disorders. Int J Mol Sci. 2021;22(21):11410. doi:10.3390/ijms222111410.
60. Ahn SH, Khalaj K, Young SL, Lessey BA, Koti M, Tayade C. Immune-inflammation gene signatures in endometriosis patients. Fertil Steril. 2016;106(6):1420–1431.e7. doi:10.1016/j.fertnstert.2016.07.005.
61. Ishii K, Takakuwa K, Kashima K, Tamura M, Tanaka K. Associations between endometriosis and HLA class II genotypes: analysis of HLA-DQB1 and HLA-DPB1. Hum Reprod. 2003;18(5):985–989. doi:10.1093/humrep/deg192.
62. Koumantakis EE, Panayiotides JG, Goumenou AG, Ziogos ECh, Margariti A, Kalapothaki V, Matalliotakis IM. Different HLA-DR expression in endometriotic and adenomyotic lesions: correlation with transvaginal ultrasonography findings. Arch Gynecol Obstet. 2010;281(5):851–856. doi:10.1007/s00404-009-1168-z.
63. Ruan J, Tian Q, Li S, Zhou X, Sun Q, Wang Y, et al. The IL-33–ST2 axis plays a vital role in endometriosis via promoting epithelial–mesenchymal transition by phosphorylating β-catenin. Cell Commun Signal. 2024;22(1):318. doi:10.1186/s12964-024-01683-x.
64. Zheng QM, Chen XY, Bao QF, Yu J, Chen LH. ILK enhances migration and invasion abilities of human endometrial stromal cells by facilitating epithelial–mesenchymal transition. Gynecol Endocrinol. 2018;34(12):1091–1096. doi:10.1080/09513590.2018.1498477.
65. Ridge KM, Eriksson JE, Pekny M, Goldman RD. Roles of vimentin in health and disease. Genes Dev. 2022;36(7–8):391–407. doi:10.1101/gad.349358.122.
66. Fang S, Dai Y, Mei Y, Yang M, Hu L, Yang H, et al. Clinical significance and biological role of cancer-derived type I collagen in lung and esophageal cancers. Thorac Cancer. 2019;10(2):277–288. doi:10.1111/1759-7714.12947.
67. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15(12):1243–1253. doi:10.15252/embr.201439246.
68. Zhang Q, Duan J, Liu X, Guo SW. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial–mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 2016;428:1–16. doi:10.1016/j.mce.2016.03.015.
69. Guo SW. Fibrogenesis resulting from cyclic bleeding: the Holy Grail of the natural history of ectopic endometrium. Hum Reprod. 2018;33(3):353–356. doi:10.1093/humrep/dey015.
70. Dai W, Guo R, Na X, Jiang S, Liang J, Guo C, et al. Hypoxia and the endometrium: an indispensable role for HIF-1α as therapeutic strategies. Redox Biol. 2024;73:103205. doi:10.1016/j.redox.2024.103205.
71. Xiong Y, Liu Y, Xiong W, Zhang L, Liu H, Du Y, et al. Hypoxia-inducible factor 1α-induced epithelial–mesenchymal transition of endometrial epithelial cells may contribute to the development of endometriosis. Hum Reprod. 2016;31(6):1327–1338. doi:10.1093/humrep/dew081.
72. Ilic M, et al. Overexpression of senescence-associated beta-galactosidase (SA-β-GAL) as a prognostic marker of invasive breast carcinoma. Exp Appl Biomed Res. 2025;26(1):39–52. doi:10.2478/eabr-2025-0001.
73. Xiao S, Qin D, Hou X, Tian L, Yu Y, Zhang R, et al. Cellular senescence: a double-edged sword in cancer therapy. Front Oncol. 2023;13:1189015. doi:10.3389/fonc.2023.1189015.
74. Kong X, Zheng Z, Song G, Zhang Z, Liu H, Kang J, et al. Over-expression of GUSB leads to primary resistance of anti-PD-1 therapy in hepatocellular carcinoma. Front Immunol. 2022;13:876048. doi:10.3389/fimmu.2022.876048.
75. Azeze GG, Wu L, Alemu BK, Lee WF, Fung LWY, Cheung ECW, et al. Proteomics approach to discovering non-invasive diagnostic biomarkers and understanding the pathogenesis of endometriosis: a systematic review and meta-analysis. J Transl Med. 2024;22(1):685. doi:10.1186/s12967-024-05474-3.
76. Yu Z, Huang P, Wang L, Meng F, Shi Q, Huang X, et al. Monoamine oxidases activity maintains endometrial monoamine homeostasis and participates in embryo implantation and development. BMC Biol. 2024;22(1):166. doi:10.1186/s12915-024-01966-2.
77. Bevanda Glibo D, Bevanda D, Vukojević K, et al. IMP3 protein is an independent prognostic factor of clinical stage II rectal cancer. Sci Rep. 2021;11:10844. doi:10.1038/s41598-021-90513-y.
78. Bilir C, Sarisozen C. Indoleamine 2,3-dioxygenase (IDO): only an enzyme or a checkpoint controller? J Oncol Sci. 2017;3(2):52–56. doi:10.1016/j.jons.2017.04.001.
79. Yang HL, Li MQ. Indoleamine 2,3-dioxygenase in endometriosis. Reprod Dev Med. 2019;3(2):110–116. doi:10.4103/2096-2924.262391.
80. Aydin H, Bat B, Cetinavci D, et al. Immunohistochemical examination of CD163 and TROP2 expression levels in ovarian endometriosis. J Mol Histol. 2025;56:271. doi:10.1007/s10735-025-10569-2.
81. Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022;10(24):1403. doi:10.21037/atm-22-5976.
82. Wang J, Garbutt C, Ma H, Gao P, Hornicek FJ, Kan Q, et al. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug-resistant ovarian cancer. Gynecol Oncol. 2018;150(1):143–150. doi:10.1016/j.ygyno.2018.04.557.
83. Iwadate R, Inoue J, Tsuda H, Takano M, Furuya K, Hirasawa A, et al. High expression of SQSTM1/p62 protein is associated with poor prognosis in epithelial ovarian cancer. Acta Histochem Cytochem. 2014;47(6):295–301. doi:10.1267/ahc.14048.
84. Birbo B, Madu EE, Madu CO, Jain A, Lu Y. Role of HSP90 in cancer. Int J Mol Sci. 2021;22(19):10317. doi:10.3390/ijms221910317.
85. Zavareh RB, Spangenberg SH, Woods A, Martínez-Peña F, Lairson LL. HSP90 inhibition enhances cancer immunotherapy by modulating the surface expression of multiple immune checkpoint proteins. Cell Chem Biol. 2021;28(2):158–168.e5. doi:10.1016/j.chembiol.2020.10.005.
86. Hoter A, Naim HY. Heat shock proteins and ovarian cancer: important roles and therapeutic opportunities. Cancers (Basel). 2019;11(9):1389. doi:10.3390/cancers11091389.
87. Guo D, Meng Y, Jiang X, Lu Z. Hexokinases in cancer and other pathologies. Cell Insight. 2023;2(1):100077. doi:10.1016/j.cellin.2023.100077.
88. Zhao Y, Zhang Y, Lu W, et al. The diagnostic/prognostic roles and biological function of the IFIT family members in acute myeloid leukemia. BMC Med Genomics. 2023;16:296. doi:10.1186/s12920-023-01735-0.
89. Kader T, Lin JR, Hug C, Coy S, Chen YA, de Bruijn I, et al. Multimodal spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to high-grade serous ovarian carcinoma. bioRxiv [Preprint]. 2024;2024.09.25.615007. doi:10.1101/2024.09.25.615007. Updated in: Cancer Discov. 2025;15(6):1180–1202. doi:10.1158/2159-8290.CD-24-1366.
90. Luo W, Zhang D, Lin Z, Zhuang J, Liang S, Huang Z, et al. Interferon-stimulated gene subtypes as key indicators of immune landscape and survival outcomes in ovarian cancer. Discov Oncol. 2024;15(1):775. doi:10.1007/s12672-024-01617-6.
91. Greygoose E, Metharom P, Kula H, Seckin TK, Seckin TA, Ayhan A, et al. The estrogen–immune interface in endometriosis. Cells. 2025;14(1):58. doi:10.3390/cells14010058.
92. Wilson TR, Peterson KR, Morris SA, Kuhnell D, Kasper S, Burns KA. Neutrophils initiate proinflammatory immune responses in early endometriosis lesion development. JCI Insight. 2025;10(5):e186133. doi:10.1172/jci.insight.186133.
93. Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, et al. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol. 2011;121(1):181–186. doi:10.1016/j.ygyno.2010.11.019.
94. Yu TT, Wang CY, Tong R. ERBB2 gene expression silencing involved in ovarian cancer cell migration and invasion through mediating MAPK1/MAPK3 signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(10):5267–5280. doi:10.26355/eurrev_202005_21309.
95. Bonello M, Sims AH, Langdon SP. Human epidermal growth factor receptor–targeted inhibitors for the treatment of ovarian cancer. Cancer Biol Med. 2018;15(4):375–388. doi:10.20892/j.issn.2095-3941.2018.0062.
96. Tan HS, Jiang WH, He Y, Wang DS, Wu ZJ, Wu DS, et al. KRT8 upregulation promotes tumor metastasis and is predictive of a poor prognosis in clear cell renal cell carcinoma. Oncotarget. 2017;8(44):76189–76203. doi:10.18632/oncotarget.19198.
97. Li X, Shan W, Peng W, Zhu Q, Huang X, Chen Y, et al. Identification of endoplasmic reticulum stress-related gene signature reveals KRT8 as a target in ovarian cancer. Clin Lab. 2025;71(12). doi:10.7754/Clin.Lab.2025.241216.
98. Busch T, Armacki M, Eiseler T, Joodi G, Temme C, Jansen J, et al. Keratin 8 phosphorylation regulates keratin reorganization and migration of epithelial tumor cells. J Cell Sci. 2012;125(Pt 9):2148–2159. doi:10.1242/jcs.080127.
99. Ku NO, Omary MB. Phosphorylation of human keratin 8 in vivo at conserved head domain serine 23 and at epidermal growth factor-stimulated tail domain serine 431. J Biol Chem. 1997;272(11):7556–7564. doi:10.1074/jbc.272.11.7556.
100. Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc. 2012;7(9):1755–1764. doi:10.1038/nprot.2012.097.
101. Guo J, Sheng G, Warner BW. Epidermal growth factor–induced rapid retinoblastoma phosphorylation at Ser780 and Ser795 is mediated by ERK1/2 in small intestine epithelial cells. J Biol Chem. 2005;280(43):35992–35998. doi:10.1074/jbc.M504583200.
102. Matellan C, Lachowski D, Cortes E, et al. Retinoic acid receptor β modulates mechanosensing and invasion in pancreatic cancer cells via myosin light chain 2. Oncogenesis. 2023;12:23. doi:10.1038/s41389-023-00467-1.
103. Matsuzaki S, Canis M, Pouly JL, Darcha C. Soft matrices inhibit cell proliferation and inactivate the fibrotic phenotype of deep endometriotic stromal cells in vitro. Hum Reprod. 2016;31(3):541–553. doi:10.1093/humrep/dev333.
104. Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7(10):11018–11032. doi:10.18632/oncotarget.6920.
105. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018;127(2):175–186. doi:10.1007/s00412-018-0659-8.
106. Gu NH, Li GJ, Yang BX, You M, Lin Y, Sun F, et al. Hypo-expression of tuberin promotes adenomyosis via the mTOR1–autophagy axis. Front Cell Dev Biol. 2021;9:710407. doi:10.3389/fcell.2021.710407.
107. Mei J, Zhou WJ, Zhu XY, Lu H, Wu K, Yang HL, et al. Suppression of autophagy and HCK signaling promotes PTGS2^high FCGR3^− NK cell differentiation triggered by ectopic endometrial stromal cells. Autophagy. 2018;14(8):1376–1397. doi:10.1080/15548627.2018.1476809.
108. Kumar S, Sánchez-Álvarez M, Lolo FN, Trionfetti F, Strippoli R, Cordani M. Autophagy and the lysosomal system in cancer. Cells. 2021;10(10):2752. doi:10.3390/cells10102752.
109. Perera RM, Zoncu R. The lysosome as a regulatory hub. Annu Rev Cell Dev Biol. 2016;32:223–253. doi:10.1146/annurev-cellbio-111315-125125.
110. Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):177–200. doi:10.1016/j.bpobgyn.2004.01.007. PMID:15157637.
-
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/101743-
dc.description.abstract標題: 使用 GeoMx 數位空間分析技術進行子宮內膜異位症相關卵巢透明細胞癌的空間蛋白質體分析

背景: 子宮內膜異位症是一種慢性發炎與纖維化的婦科疾病,且長期以來被證實與卵巢透明細胞癌(ovarian clear cell carcinoma, OCCC)之發生風險增加密切相關。儘管兩者之間的流行病學關聯已被廣泛建立,目前針對辨識具有惡性轉化風險之子宮內膜異位症患者的策略仍然不足,且在疾病進展過程中,上皮、免疫與基質微環境層級的生物學變化仍存在顯著知識缺口。傳統的整體(bulk)分子分析方法缺乏空間解析度,無法保留組織內的空間脈絡,因而限制了對不同組織區室中特定生物學程式的理解,而這些程式可能正是子宮內膜異位症相關卵巢癌發生的關鍵基礎。

方法: 本研究採用 NanoString GeoMx® 數位空間分析技術(Digital Spatial Profiling, DSP),結合免疫腫瘤蛋白質體圖譜(Immuno-Oncology Proteome Atlas),進行空間蛋白質體分析,以比較子宮內膜異位症、原發性卵巢透明細胞癌與復發性卵巢透明細胞癌之蛋白質表現特徵。研究分析來自兩位患者的福馬林固定石蠟包埋(FFPE)組織切片,並依據空間分布劃分為三個明確的組織區室:PanCK⁺ 上皮區、CD45⁺ 免疫區,以及 PanCK⁻/CD45⁻ 基質區。於各區室內分別進行不同疾病狀態之蛋白質差異表現分析。蛋白質體結果進一步結合 NanoString 所提供之癌症標誌(Hallmarks of Cancer)主題性註解,透過關聯層級(association-level)分析架構,以辨識與疾病進展相關的主要生物學模式。

結果: 子宮內膜異位症呈現出一種以纖維化與發炎為主、並適應低氧環境的微環境特徵,表現為細胞外基質重塑、免疫參與,以及代謝壓力調適等生物學程式,且此現象橫跨所有組織區室。原發性卵巢透明細胞癌則顯示上述壓力適應程式的進一步放大,並伴隨顯著的上皮細胞增殖訊號、上皮結構穩定性,以及高度代謝需求的腫瘤相關免疫表型。復發性卵巢透明細胞癌則以「選擇性強化」之持續存活導向特徵為主要表現,包括增殖優勢的進一步主導、上皮收縮性增加,以及與溶酶體運輸及上皮—免疫介面互動相關的免疫調適機制。整體而言,多項癌症標誌相關主題在不同疾病狀態中持續存在,包括細胞能量代謝失衡、促腫瘤性發炎反應、侵襲相關程式的活化,以及免疫逃避機制。

結論: 本研究結果支持一個疾病連續體模型,顯示子宮內膜異位症雖屬非惡性狀態,但其微環境已具備生物學上被「預先啟動」的特徵,並與卵巢透明細胞癌共享多項關鍵分子特徵。惡性轉化與復發過程似乎並非源自全新生物狀態的出現,而是透過既有壓力適應程式的放大與選擇性強化而逐步形成。空間蛋白質體分析能夠提供對不同組織區室中微環境演化的關鍵洞見,並突顯以微環境為核心的研究策略,對於理解子宮內膜異位症相關卵巢透明細胞癌之發生與進展具有重要意義。
zh_TW
dc.description.abstractTitle: Spatial Proteomic Profiling of Endometriosis-Associated Ovarian Clear Cell Carcinoma Using GeoMx Digital Spatial Profiling

Background: Endometriosis is a chronic inflammatory and fibrotic gynecologic disorder that has been consistently associated with an increased risk of ovarian clear cell carcinoma (OCCC). Despite this epidemiological link, strategies to identify endometriosis patients at risk of malignant transformation remain underdeveloped, and significant gaps persist in understanding how disease progression occurs at the level of the epithelial, immune, and stromal microenvironments. Traditional bulk molecular analyses obscure spatial context, limiting insight into compartment-specific biological programs that may underlie endometriosis-associated ovarian carcinogenesis.

Methods: In this study, spatial proteomic profiling was performed using NanoString GeoMx® Digital Spatial Profiling with the Immuno-Oncology Proteome Atlas to compare endometriosis, primary OCCC, and recurrent OCCC. Formalin-fixed paraffin-embedded (FFPE) tissue sections from two patients were analyzed across three spatially defined compartments: PanCK⁺ epithelial, CD45⁺ immune, and PanCK⁻/CD45⁻ stromal regions. Differential protein expression analyses were conducted for disease-state comparisons within each compartment. Proteomic findings were interpreted using an association-level framework based on NanoString’s Hallmarks of Cancer thematic annotations to identify dominant biological patterns associated with disease progression.

Results: Endometriosis exhibited a fibro-inflammatory, hypoxia-adapted microenvironment characterized by extracellular matrix remodeling, immune engagement, and metabolic stress adaptation across all compartments. Primary OCCC demonstrated amplification of these stress-adaptive programs, with marked enrichment of epithelial proliferative signaling, epithelial cohesion, and metabolically demanding tumor-associated immune profiles. Recurrent OCCC was distinguished by selective reinforcement of persistence-oriented features, including proliferation dominance, increased epithelial contractility, and immune adaptation linked to lysosomal trafficking and epithelial–immune interface association. Hallmark-associated themes were maintained across disease states, including deregulated cellular energetics, tumor-promoting inflammation, activation of invasion-associated programs, and avoidance of immune destruction.

Conclusions: These findings support a continuum model in which endometriosis represents a biologically primed but non-malignant microenvironment that shares key molecular features with OCCC. Malignant transformation and recurrence appear to arise through amplification and selective reinforcement of pre-existing stress-adaptive programs rather than the emergence of entirely novel biological states. Spatial proteomic profiling provides critical insight into compartment-specific microenvironmental evolution and underscores the importance of microenvironment-focused approaches for understanding endometriosis-associated ovarian clear cell carcinoma.
en
dc.description.provenanceSubmitted by admin ntu (admin@lib.ntu.edu.tw) on 2026-03-04T16:13:04Z
No. of bitstreams: 0
en
dc.description.provenanceMade available in DSpace on 2026-03-04T16:13:04Z (GMT). No. of bitstreams: 0en
dc.description.tableofcontentsMaster’s Thesis Acceptance Certificate .................................................. II
Acknowledgment ............................................................................................. III
Abstract ............................................................................................................ V
Contents ............................................................................................................ VIII
Chapter 1: Introduction and Literature Review ............................................. 1
1.1 Ovarian Clear Cell Carcinoma ................................................................. 1
1.2 Endometriosis ........................................................................................... 2
1.3 Endometriosis-Associated Ovarian Cancer (EAOC) ............................... 3
1.4 Tumor Microenvironment and Spatial Compartments ............................. 4
1.5 Hallmarks of Cancer and Endometriosis .................................................. 6
1.6 From Bulk Omics to Spatial Proteomics .................................................. 7
1.7 Digital Spatial Profiling and the GeoMX DSP Platform ........................ 8
1.8 Knowledge Gaps and Rationale for the Present Study ............................ 9
1.9 Research Question, Hypothesis, and Objectives ...................................... 10

Chapter 2: Materials and Methods ................................................................. 13
2.1 Experimental Design ............................................................................... 13
2.2 GeoMx DSP Workflow ............................................................................ 16
(i) GeoMx Manual Slide Preparation for Protein FFPE Profiling ............... 17
(ii) GeoMx DSP Instrument: Imaging, ROI Selection, and Segmentation .... 19
(iii) Next Generation Sequencing (NGS) Readout ........................................ 20
2.3 Data Analysis ........................................................................................... 20
Part I: GeoMx DSP Data Analysis Suite ......................................................... 20
Part II: Protein-level Differential Expression Analysis .................................. 24

Chapter 3: Results ............................................................................................ 26
3.1 Endometriosis Versus Primary OCCC ..................................................... 27
3.1.1 PanCK⁺ Epithelial Compartment ......................................................... 27
3.1.2 CD45⁺ Immune Compartment ............................................................... 36
3.1.3 PanCK⁻/CD45⁻ Stromal Compartment ................................................. 43
3.2 Primary OCCC Versus Recurrent OCCC ................................................ 49
3.2.1 PanCK⁺ Epithelial Compartment ......................................................... 49
3.2.2 CD45⁺ Immune Compartment ............................................................... 52
3.2.3 PanCK⁻/CD45⁻ Stromal Compartment ................................................. 55
3.3 Endometriosis Versus Recurrent OCCC .................................................. 57
3.3.1 PanCK⁺ Epithelial Compartment ......................................................... 57
3.3.2 CD45⁺ Immune Compartment ............................................................... 62
3.3.3 PanCK⁻/CD45⁻ Stromal Compartment ................................................. 68

Chapter 4: Discussion ....................................................................................... 71
4.1 Overview of Major Findings and Disease Continuum ............................ 71
4.2 Microenvironmental Priming in Endometriosis as a Precursor State ..... 72
4.3 Transition to Primary Ovarian Clear Cell Carcinoma: Amplification of Stress-Adaptive Programs ............................................................................. 74
4.4 Biological Features of Recurrent Ovarian Clear Cell Carcinoma ........... 75
4.5 Immune Microenvironment Evolution: From Chronic Inflammation to Immune Suppression ...................................................................................... 76
4.6 Stromal Compartment and Fibro-Inflammatory Support of Disease Progression ..................................................................................................... 77
4.7 Spatial Proteomic Technology in Context: Strengths and Constraints .. 78
4.8 Study Limitations and Future Directions ................................................. 79
4.9 Clinical Implications ................................................................................ 81

Chapter 5: Conclusion ....................................................................................... 81

References ........................................................................................................ 85

Annexes ............................................................................................................ 91
-
dc.language.isoen-
dc.subject子宮內膜異位症-
dc.subject卵巢透明細胞癌-
dc.subject空間蛋白質體學-
dc.subjectGeoMx 數位空間分析-
dc.subject腫瘤微環境-
dc.subject免疫腫瘤蛋白質體圖譜-
dc.subject疾病連續體-
dc.subject癌症標誌-
dc.subjectEndometriosis-
dc.subjectOvarian Clear Cell Carcinoma-
dc.subjectSpatial Proteomics-
dc.subjectGeoMx Digital Spatial Profiling-
dc.subjectTumor Microenvironment-
dc.subjectImmuno-Oncology Proteome Atlas-
dc.subjectDisease Continuum-
dc.subjectHallmarks of Cancer-
dc.title使用 GeoMx 數位空間分析技術進行子宮內膜異位症相關卵巢透明細胞癌的空間蛋白質體分析zh_TW
dc.titleSpatial Proteomic Profiling of Endometriosis-Associated Ovarian Clear Cell Carcinoma Using GeoMx Digital Spatial Profilingen
dc.typeThesis-
dc.date.schoolyear114-1-
dc.description.degree碩士-
dc.contributor.oralexamcommittee林維洲;洪維廷zh_TW
dc.contributor.oralexamcommitteeWEI-CHOU LIN;WEI-TING HUNGen
dc.subject.keyword子宮內膜異位症,卵巢透明細胞癌空間蛋白質體學GeoMx 數位空間分析腫瘤微環境免疫腫瘤蛋白質體圖譜疾病連續體癌症標誌zh_TW
dc.subject.keywordEndometriosis,Ovarian Clear Cell CarcinomaSpatial ProteomicsGeoMx Digital Spatial ProfilingTumor MicroenvironmentImmuno-Oncology Proteome AtlasDisease ContinuumHallmarks of Canceren
dc.relation.page141-
dc.identifier.doi10.6342/NTU202600673-
dc.rights.note同意授權(全球公開)-
dc.date.accepted2026-02-23-
dc.contributor.author-college共同教育中心-
dc.contributor.author-dept智慧醫療與健康資訊碩士學位學程-
dc.date.embargo-lift2026-03-05-
顯示於系所單位:智慧醫療與健康資訊碩士學位學程

文件中的檔案:
檔案 大小格式 
ntu-114-1.pdf225.92 MBAdobe PDF檢視/開啟
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved